{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:22:32Z","timestamp":1762507352621},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00774-018-0915-2","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T05:14:47Z","timestamp":1520831687000},"page":"292-300","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Satoshi","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kakihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Furuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/PL00004148","volume":"7","author":"B Gullberg","year":"1997","unstructured":"Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407\u2013413","journal-title":"Osteoporos Int"},{"key":"915_CR2","unstructured":"Editorial Committee on Guidelines for Prevention and Treatment of Osteoporosis (2015) Guidelines for prevention and treatment of osteoporosis. Japan Osteoporosis Society, Tokyo, Japan (in Japanese)"},{"key":"915_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00198-015-3464-8","volume":"27","author":"H Orimo","year":"2016","unstructured":"Orimo H, Yaegashi Y, Hosoi T, Fukushima Y, Onoda T, Hashimoto T, Sakata K (2016) Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int 27:1777\u20131784","journal-title":"Osteoporos Int"},{"key":"915_CR4","first-page":"509","volume":"10","author":"Z Xu","year":"2016","unstructured":"Xu Z, Fan C, Zhao X, Tao H (2016) Treatment of osteoporosis with eldecalcitol, a new vitamin\u00a0D analog: a comprehensive review and meta-analysis of randomized clinical trials. Drug Des Devel Ther 10:509\u2013517","journal-title":"Drug Des Devel Ther"},{"key":"915_CR5","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1210\/jc.2004-2552","volume":"90","author":"T Matsumoto","year":"2005","unstructured":"Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin\u00a0D, ED-71, increases bone mass in osteoporotic patients under vitamin\u00a0D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90:5031\u20135036","journal-title":"J Clin Endocrinol Metab"},{"key":"915_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin\u00a0D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49:605\u2013612","journal-title":"Bone"},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00198-014-2991-z","volume":"26","author":"A Sakai","year":"2015","unstructured":"Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group (2015) Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin\u00a0D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int 26:1193\u20131202","journal-title":"Osteoporos Int"},{"key":"915_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00774-016-0779-2","volume":"35","author":"H Saito","year":"2017","unstructured":"Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y, Tabata H, Nomura M (2017) The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab 35:456\u2013463","journal-title":"J Bone Miner Metab"},{"key":"915_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"915_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"915_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110\u2013113","journal-title":"Rheumatol Int"},{"key":"915_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","volume":"29","author":"JD Ringe","year":"2009","unstructured":"Ringe JD, Farahmand P, Faber H, Dorst A (2009) Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 29:311\u2013315","journal-title":"Rheumatol Int"},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719\u2013725","journal-title":"J Bone Miner Res"},{"key":"915_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970\u2013976","journal-title":"Bone"},{"key":"915_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"915_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714\u20131723","journal-title":"N Engl J Med"},{"key":"915_CR17","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5\u00a0mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239\u20132350","journal-title":"J Bone Miner Res"},{"key":"915_CR18","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbj\u00e6rg CS, Langdahl BL, Chapurlat R, Czerwinski E et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169","journal-title":"J Clin Endocrinol Metab"},{"key":"915_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbj\u00e6rg CS, Ho PR, Chapurlat R, Czerwinski E et al (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100:1335\u20131342","journal-title":"J Clin Endocrinol Metab"},{"key":"915_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"915_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510\u2013516","journal-title":"Osteoporos Int"},{"key":"915_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jsbmb.2015.01.016","volume":"148","author":"S Kondo","year":"2015","unstructured":"Kondo S, Takano T, Ono Y, Saito H, Matsumoto T (2015) Eldecalcitol reduces osteoporotic fractures by unique mechanisms. J Steroid Biochem Mol Biol 148:232\u2013238","journal-title":"J Steroid Biochem Mol Biol"},{"key":"915_CR23","unstructured":"Japanese package insert for Edirol\u00ae Capsule. 2016. Online. Available: \n                    https:\/\/chugai-pharm.jp\/hc\/ss\/pr\/drug\/edr_cap0075\/pi\/PDF\/edr_pi.pdf\n                    \n                  . Accessed May, 2017 (in Japanese)"},{"key":"915_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.5414\/CP202072","volume":"52","author":"S Tomkov\u00e1","year":"2014","unstructured":"Tomkov\u00e1 S, Telepkov\u00e1 D, Vanuga P, Killinger Z, Sulkov\u00e1 I, Celec P, Payer J (2014) Therapeutic adherence to osteoporosis treatment. Int J Clin Pharmacol Ther 52:663\u2013668","journal-title":"Int J Clin Pharmacol Ther"},{"key":"915_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652","journal-title":"Osteoporos Int"},{"key":"915_CR26","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar3107","volume":"12","author":"SY Kim","year":"2010","unstructured":"Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH (2010) Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12:R154","journal-title":"Arthritis Res Ther"},{"key":"915_CR27","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3899\/jrheum.100363","volume":"37","author":"RJ Weiss","year":"2010","unstructured":"Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case-control study with 53,108 patients with fracture. J Rheumatol 37:2247\u20132250","journal-title":"J Rheumatol"},{"key":"915_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00198-015-3279-7","volume":"27","author":"Y Fan","year":"2016","unstructured":"Fan Y, Wei F, Lang Y, Liu Y (2016) Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int 27:219\u2013228","journal-title":"Osteoporos Int"},{"key":"915_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495\u2013505","journal-title":"Am J Epidemiol"},{"key":"915_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a metaanalysis. Osteoporos Int 18:427\u2013444","journal-title":"Osteoporos Int"},{"key":"915_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00198-013-2438-y","volume":"25","author":"CL Gregson","year":"2014","unstructured":"Gregson CL, Dennison EM, Compston JE, Adami S, Adachi JD et al (2014) Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 25:85\u201395","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0915-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-018-0915-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0915-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:18:29Z","timestamp":1567073909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-018-0915-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1007\/s00774-018-0915-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"24 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors except YK are employees of Chugai Pharmaceutical Co., Ltd. YK is an employee of Taisho Toyama Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}